NEW YORK, Feb. 4, 2021 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. (“Sarepta” or the “Enterprise”)(NASDAQ: SRPT).  This kind of investors are advised to make contact with Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980.

The investigation concerns no matter if Sarepta and sure of its officers and/or directors have engaged in securities fraud or other illegal business enterprise procedures. 

[Click here for information about joining the class action] 

On January 7, 2021, Sarepta issued a push release asserting prime-line results for Part 1 of the Company’s Research SRP-9001-102 (“Research 102”), “an ongoing, randomized, double-blind, placebo-controlled clinical demo to evaluate the safety, efficacy and tolerability of a one dose of SRP-9001 (rAAVrh74.MHCK7.micro-dystrophin) in 41 people with Duchenne muscular dystrophy. SRP-9001 is an investigational gene transfer treatment meant to supply its micro-dystrophin-encoding gene to muscle mass tissue for the targeted production of the micro-dystrophin protein.”  Whilst Sarepta touted the simple fact that Study 102 met its principal organic endpoint “[a]t 12 months publish-remedy compared to baseline,” the products candidate unsuccessful to coincide with statistically considerable enhancements in muscle mass operate for all individuals immediately after 1 12 months. 

On this news, Sarepta’s inventory cost fell $86.66 for each share, or 51.29%, to shut at $82.29 for each share on January 8, 2021.&#13

The Pomerantz Business, with places of work in New York, Chicago, Los Angeles, and Paris is acknowledged as 1 of the premier corporations in the areas of corporate, securities, and antitrust course litigation. Launched by the late Abraham L. Pomerantz, recognized as the dean of the class action bar, the Pomerantz Agency pioneered the industry of securities course actions. Nowadays, far more than 80 decades later on, the Pomerantz Company proceeds in the tradition he set up, preventing for the rights of the victims of securities fraud, breaches of fiduciary responsibility, and corporate misconduct. The Organization has recovered a lot of multimillion-dollar damages awards on behalf of class users. See www.pomerantzlaw.com.

Call:
Robert S. Willoughby
Pomerantz LLP
[email protected] 
888-476-6529 ext. 7980

View primary information:https://www.prnewswire.com/news-releases/shareholder-warn-pomerantz-law-firm-investigates-promises-on-behalf-of-buyers-of-sarepta-therapeutics-inc—srpt-301222816.html

Supply Pomerantz LLP